{
  "Metformin": {
    "chat": {
      "user": "Metformin for Oncology",
      "ai": "Analysis completed using Agentic AI."
    },
    "original_indication": "Type 2 Diabetes",
    "repurposing_target": "Oncology (Various Cancers)",
    "key_mechanism_class": "AMPK Activator",
    "agent_status": [
      "Scientific Agent completed",
      "Clinical Agent completed",
      "Regulatory Agent completed",
      "Patent Agent completed",
      "Market Agent completed"
    ],
    "insights": [
      "AMPK activation linked to tumor metabolism regulation",
      "Existing long-term safety data available",
      "Low regulatory barrier due to prior approval",
      "High interest in oncology adjunct therapies"
    ],
    "confidence_score": 0.88
  },

  "Losartan": {
    "chat": {
      "user": "Losartan for Diabetic Nephropathy",
      "ai": "Analysis completed using Agentic AI."
    },
    "original_indication": "Hypertension",
    "repurposing_target": "Diabetic Nephropathy",
    "key_mechanism_class": "Angiotensin Receptor Blocker (ARB)",
    "agent_status": [
      "Scientific Agent completed",
      "Clinical Agent completed",
      "Regulatory Agent completed",
      "Patent Agent completed",
      "Market Agent completed"
    ],
    "insights": [
      "Renoprotective effects demonstrated in diabetic patients",
      "Strong clinical evidence in kidney disease",
      "Minimal regulatory risk",
      "Large chronic kidney disease market"
    ],
    "confidence_score": 0.86
  },

  "Atorvastatin": {
    "chat": {
      "user": "Atorvastatin for Alzheimer's Disease",
      "ai": "Analysis completed using Agentic AI."
    },
    "original_indication": "Hyperlipidemia",
    "repurposing_target": "Alzheimer's Disease",
    "key_mechanism_class": "HMG-CoA Reductase Inhibitor",
    "agent_status": [
      "Scientific Agent completed",
      "Clinical Agent completed",
      "Regulatory Agent completed",
      "Patent Agent completed",
      "Market Agent completed"
    ],
    "insights": [
      "Cholesterol metabolism implicated in neurodegeneration",
      "Mixed but promising clinical signals",
      "Well-established cardiovascular safety",
      "High unmet neurological market need"
    ],
    "confidence_score": 0.73
  },

  "Amlodipine": {
    "chat": {
      "user": "Amlodipine for Raynaud's Phenomenon",
      "ai": "Analysis completed using Agentic AI."
    },
    "original_indication": "Hypertension",
    "repurposing_target": "Raynaud's Phenomenon",
    "key_mechanism_class": "Calcium Channel Blocker (CCB)",
    "agent_status": [
      "Scientific Agent completed",
      "Clinical Agent completed",
      "Regulatory Agent completed",
      "Patent Agent completed",
      "Market Agent completed"
    ],
    "insights": [
      "Peripheral vasodilation improves blood flow",
      "Off-label vascular use already documented",
      "Low safety concerns",
      "Niche but clinically relevant market"
    ],
    "confidence_score": 0.75
  },

  "Sildenafil": {
    "chat": {
      "user": "Sildenafil for Alzheimer's Disease",
      "ai": "Analysis completed using Agentic AI."
    },
    "original_indication": "Erectile Dysfunction / PAH",
    "repurposing_target": "Alzheimer's Disease / Peripheral Neuropathy",
    "key_mechanism_class": "PDE5 Inhibitor",
    "agent_status": [
      "Scientific Agent completed",
      "Clinical Agent completed",
      "Regulatory Agent completed",
      "Patent Agent completed",
      "Market Agent completed"
    ],
    "insights": [
      "Improved cerebral blood flow observed",
      "Neuroprotective hypotheses under investigation",
      "Established human safety profile",
      "Growing neurodegenerative disease burden"
    ],
    "confidence_score": 0.77
  },

  "Diclofenac": {
    "chat": {
      "user": "Diclofenac for Actinic Keratosis",
      "ai": "Analysis completed using Agentic AI."
    },
    "original_indication": "Pain / Inflammation",
    "repurposing_target": "Actinic Keratosis",
    "key_mechanism_class": "NSAID",
    "agent_status": [
      "Scientific Agent completed",
      "Clinical Agent completed",
      "Regulatory Agent completed",
      "Patent Agent completed",
      "Market Agent completed"
    ],
    "insights": [
      "COX inhibition reduces abnormal keratinocyte growth",
      "Topical formulations already approved",
      "Low regulatory complexity",
      "Dermatology outpatient market opportunity"
    ],
    "confidence_score": 0.82
  },

  "Aspirin": {
    "chat": {
      "user": "Aspirin for Colorectal Cancer Prevention",
      "ai": "Analysis completed using Agentic AI."
    },
    "original_indication": "Analgesic / Antiplatelet",
    "repurposing_target": "Colorectal Cancer Prevention",
    "key_mechanism_class": "COX Inhibitor",
    "agent_status": [
      "Scientific Agent completed",
      "Clinical Agent completed",
      "Regulatory Agent completed",
      "Patent Agent completed",
      "Market Agent completed"
    ],
    "insights": [
      "Anti-inflammatory action linked to cancer prevention",
      "Strong epidemiological evidence",
      "Low cost and wide availability",
      "Preventive oncology market potential"
    ],
    "confidence_score": 0.84
  },

  "Ibuprofen": {
    "chat": {
      "user": "Ibuprofen for Chronic Back Pain",
      "ai": "Analysis completed using Agentic AI."
    },
    "original_indication": "Pain / Inflammation",
    "repurposing_target": "Chronic Back Pain",
    "key_mechanism_class": "NSAID",
    "agent_status": [
      "Scientific Agent completed",
      "Clinical Agent completed",
      "Regulatory Agent completed",
      "Patent Agent completed",
      "Market Agent completed"
    ],
    "insights": [
      "Prostaglandin inhibition supports pain control",
      "Extensive real-world usage data",
      "Known GI risks manageable",
      "Large musculoskeletal disorder market"
    ],
    "confidence_score": 0.78
  },

  "Paracetamol": {
    "chat": {
      "user": "Paracetamol for Neuropathic Pain",
      "ai": "Analysis completed using Agentic AI."
    },
    "original_indication": "Analgesic / Antipyretic",
    "repurposing_target": "Neuropathic Pain",
    "key_mechanism_class": "Non-opioid Analgesic",
    "agent_status": [
      "Scientific Agent completed",
      "Clinical Agent completed",
      "Regulatory Agent completed",
      "Patent Agent completed",
      "Market Agent completed"
    ],
    "insights": [
      "Central pain modulation mechanisms suggested",
      "Excellent long-term safety",
      "Low abuse potential",
      "High unmet neuropathic pain demand"
    ],
    "confidence_score": 0.76
  }
}
